Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Malka

Showing results (181-190 of 192) with videos related to

Pageof 20
Sort By:
Cell Death and Differentiation|December 2, 2020
Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patientsMarion Picard, Satoru Yonekura, Karolina Slowicka, et al.
Genes, Chromosomes & Cancer|December 11, 2022
AXIN2 germline testing in a French cohort validates pathogenic variants as a rare cause of predisposition to colorectal polyposis and cancerJulie Leclerc, Marie Beaumont, Roseline Vibert, et al.
Gastroenterology|June 12, 2024
Organoids for Functional Precision Medicine in Advanced Pancreatic CancerAlice Boilève, Jérôme Cartry, Negaar Goudarzi, et al.
Molecular & Cellular Proteomics : MCP|May 21, 2023
Large-Scale Plasma Proteome Epitome Profiling is an Efficient Tool for the Discovery of Cancer BiomarkersJozsef Lazar, Peter Antal-Szalmas, Istvan Kurucz, et al.
The New England Journal of Medicine|December 22, 2018
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Pascal Hammel, Mohamed Hebbar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2024
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)Gael S Roth, Loic Verlingue, Matthieu Sarabi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Nature Medicine|May 27, 2020
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancerMaria Paula Roberti, Satoru Yonekura, Connie P M Duong, et al.
European Journal of Cancer (Oxford, England : 1990)|February 10, 2024
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studiesAlessandro Parisi, Blandine Delaunay, Giada Pinterpe, et al.
Gastroenterology|June 28, 2015
Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating AgentsSahra Bodo, Chrystelle Colas, Olivier Buhard, et al.
Pageof 20

Showing results (181-190 of 192) with videos related to

Sort By:
Pageof 20
Cell Death and Differentiation|December 2, 2020
Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patientsMarion Picard, Satoru Yonekura, Karolina Slowicka, et al.
Genes, Chromosomes & Cancer|December 11, 2022
AXIN2 germline testing in a French cohort validates pathogenic variants as a rare cause of predisposition to colorectal polyposis and cancerJulie Leclerc, Marie Beaumont, Roseline Vibert, et al.
Gastroenterology|June 12, 2024
Organoids for Functional Precision Medicine in Advanced Pancreatic CancerAlice Boilève, Jérôme Cartry, Negaar Goudarzi, et al.
Molecular & Cellular Proteomics : MCP|May 21, 2023
Large-Scale Plasma Proteome Epitome Profiling is an Efficient Tool for the Discovery of Cancer BiomarkersJozsef Lazar, Peter Antal-Szalmas, Istvan Kurucz, et al.
The New England Journal of Medicine|December 22, 2018
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Pascal Hammel, Mohamed Hebbar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2024
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)Gael S Roth, Loic Verlingue, Matthieu Sarabi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Nature Medicine|May 27, 2020
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancerMaria Paula Roberti, Satoru Yonekura, Connie P M Duong, et al.
European Journal of Cancer (Oxford, England : 1990)|February 10, 2024
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studiesAlessandro Parisi, Blandine Delaunay, Giada Pinterpe, et al.
Gastroenterology|June 28, 2015
Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating AgentsSahra Bodo, Chrystelle Colas, Olivier Buhard, et al.
Pageof 20